TIRZEPATIDE

What it is

A peptide that mimics two appetite hormones at once instead of one. It is the intermediate step between the classic compounds, which copy only one hormone, and newer ones such as Retatrutide, which copy three.

When you eat, the gut releases hormones called incretins that signal the pancreas and the brain. Tirzepatide copies two of them: GLP-1, the best known, and GIP. By pressing both keys, the effect on appetite and blood sugar is greater than pressing only one.

What it is used for

• • Research on weight and appetite control
• • Blood glucose control
• • Studies comparing it with compounds that copy only one hormone
• • Gastric emptying and satiety signals

How it is used

Lyophilized powder. It is reconstituted with bacteriostatic water, swirled without shaking, and stored between 2 and 8 °C. In the literature it is administered once a week with gradual dose escalation, which is what makes the digestive effects tolerable ^[1].

What has been observed

Results described in the published scientific literature. They are not directions for use or health recommendations.

• • In SURPASS-1 (478 adults with type 2 diabetes, 40 weeks), weight loss was dose-dependent and ranged from 7.0 to 9.5 kg ^[1]
• • In the same trial, glycated hemoglobin fell by 1.87 to 2.07 points, versus an increase of 0.04 with placebo ^[1]
• • Between 87% and 92% of participants reached an HbA1c below 7%, versus 20% with placebo ^[1]
• • The most frequent adverse effects were digestive, mild or moderate and transient: nausea (12-18% versus 6%), diarrhea and vomiting ^[1]
• • No severe or clinically significant hypoglycemia was reported with tirzepatide in that study ^[1]

How it works

GIP / GLP-1 co-agonism

Tirzepatide (LY-3298176) is a single peptide that simultaneously activates the GIP receptor and the GLP-1 receptor ^[2]. The GLP-1 branch acts on the hypothalamic appetite centers, slows gastric emptying and enhances glucose-dependent insulin secretion.

What the GIP branch contributes

The role of GIP was debated for years. The hypothesis behind the design is that combined signaling improves insulin sensitivity in adipose tissue and enhances the effect of GLP-1 on intake beyond what GLP-1 achieves alone ^[3][4].

Position within its family

Reviews describe it as the co-agonist with the best balance between glycemic control and weight reduction in its generation, and as the reference against which newer agonists are compared ^[4][5].

State of the evidence

Clinical and extensive. A complete phase 3 program (SURPASS series) published in The Lancet and reviewed in the endocrinology literature ^[1][4][5]. As with the rest of the catalog, the material we offer is research grade: the clinical trials cited were conducted with a pharmaceutical product and under medical supervision.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.

References

1. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 2021. PubMed 34186022
2. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab, 2018. PubMed 30473097
3. Samms RJ, et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab, 2020. PubMed 32396843
4. Nauck MA, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol, 2022. PubMed 36050763
5. Drucker DJ, et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care, 2024. PubMed 38843460